Literature DB >> 24273182

Helicobacter pylori infection affects immune responses following vaccination of typhoid-naive U.S. adults with attenuated Salmonella typhi oral vaccine CVD 908-htrA.

Khitam Muhsen1, Marcela F Pasetti, Mardi K Reymann, David Y Graham, Myron M Levine.   

Abstract

BACKGROUND: We examined the association between Helicobacter pylori infection and the immune response following oral immunization of US adults with attenuated Salmonella Typhi vaccine CVD 908-htrA.
METHODS: Baseline sera from 74 volunteers without a history of typhoid fever who were immunized orally with CVD 908-htrA were tested by enzyme-linked immunosorbent assay for immunoglobin G (IgG) antibodies to H. pylori, hepatitis A antibodies (a marker of low socioeconomic status and exposure to enteric infections), and pepsinogen (PG) I and II levels (measures of gastric inflammation). IgG against S. Typhi lipopolysaccharide (LPS) O and flagella was measured before and 28 days following immunization; a ≥4-fold increase in titer from baseline constituted seroconversion.
RESULTS: Seroconversion of S. Typhi IgG LPS antibodies was significantly higher among vaccinees infected with H. pylori versus uninfected subjects: adjusted odds ratio (OR) 3.8, 95% confidence interval (CI), 1.1-12.6 (P = .03). A low PG I:PG II ratio (<5), indicating more advanced corpus gastritis, increased the odds of seroconversion of IgG S. Typhi flagella antibody (adjusted OR 6.4, 95% CI, 1.3-31.4; P = .02). Hepatitis A infection did not influence the immune response to CVD 908-htrA.
CONCLUSIONS: H. pylori infection and gastric inflammation may enhance humoral immunity to oral attenuated S. Typhi vaccine.

Entities:  

Keywords:  Helicobacter pylori; Salmonella Typhi; humoral immunity; immunogenicity; oral vaccines; serum pepsinogens

Mesh:

Substances:

Year:  2013        PMID: 24273182      PMCID: PMC3982847          DOI: 10.1093/infdis/jit625

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  43 in total

Review 1.  Helicobacter pylori infection.

Authors:  Sebastian Suerbaum; Pierre Michetti
Journal:  N Engl J Med       Date:  2002-10-10       Impact factor: 91.245

2.  Immune responses to an oral typhoid vaccine strain that is modified to constitutively express Vi capsular polysaccharide.

Authors:  Carol O Tacket; Marcela F Pasetti; Marcelo B Sztein; Sofie Livio; Myron M Levine
Journal:  J Infect Dis       Date:  2004-06-30       Impact factor: 5.226

3.  Age at acquisition of Helicobacter pylori infection: a follow-up study from infancy to adulthood.

Authors:  Hoda M Malaty; Abdalla El-Kasabany; David Y Graham; Charles C Miller; Sidd G Reddy; Sathanur R Srinivasan; Yoshio Yamaoka; Gerald S Berenson
Journal:  Lancet       Date:  2002-03-16       Impact factor: 79.321

Review 4.  Influence of gastric acidity on bacterial and parasitic enteric infections. A perspective.

Authors:  R A Giannella; S A Broitman; N Zamcheck
Journal:  Ann Intern Med       Date:  1973-02       Impact factor: 25.391

5.  A controlled field trial of liver oral typhoid vaccine Ty21a.

Authors:  M H Wahdan; C Serie; R Germanier; A Lackany; Y Cerisier; N Guerin; S Sallam; P Geoffroy; A S el Tantawi; P Guesry
Journal:  Bull World Health Organ       Date:  1980       Impact factor: 9.408

6.  Phase 2 clinical trial of attenuated Salmonella enterica serovar typhi oral live vector vaccine CVD 908-htrA in U.S. volunteers.

Authors:  C O Tacket; M B Sztein; S S Wasserman; G Losonsky; K L Kotloff; T L Wyant; J P Nataro; R Edelman; J Perry; P Bedford; D Brown; S Chatfield; G Dougan; M M Levine
Journal:  Infect Immun       Date:  2000-03       Impact factor: 3.441

7.  Serum pepsinogen II: a neglected but useful biomarker to differentiate between diseased and normal stomachs.

Authors:  Cai-yun He; Li-ping Sun; Yue-hua Gong; Qian Xu; Nan-nan Dong; Yuan Yuan
Journal:  J Gastroenterol Hepatol       Date:  2011-06       Impact factor: 4.029

8.  Evidence that cagA(+) Helicobacter pylori strains are disappearing more rapidly than cagA(-) strains.

Authors:  G I Perez-Perez; A Salomaa; T U Kosunen; B Daverman; H Rautelin; A Aromaa; P Knekt; M J Blaser
Journal:  Gut       Date:  2002-03       Impact factor: 23.059

9.  Association between Helicobacter pylori infection and increased risk of typhoid fever.

Authors:  Maharaj K Bhan; Rajiv Bahl; Sunil Sazawal; Anju Sinha; Ramesh Kumar; Dilip Mahalanabis; John D Clemens
Journal:  J Infect Dis       Date:  2002-11-14       Impact factor: 5.226

10.  Pepsinogen A, pepsinogen C, and gastrin as markers of atrophic chronic gastritis in European dyspeptics.

Authors:  N Broutet; M Plebani; C Sakarovitch; P Sipponen; F Mégraud
Journal:  Br J Cancer       Date:  2003-04-22       Impact factor: 7.640

View more
  10 in total

Review 1.  Potential for use of retinoic acid as an oral vaccine adjuvant.

Authors:  Mpala Mwanza-Lisulo; Paul Kelly
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2015-06-19       Impact factor: 6.237

2.  Does the antibody production ability affect the serum anti-Helicobacter pylori IgG titer?

Authors:  Hyun Ah Chung; Sun-Young Lee; Hee Won Moon; Jeong Hwan Kim; In-Kyung Sung; Hyung Seok Park; Chan Sup Shim; Hye Seung Han
Journal:  World J Gastrointest Pathophysiol       Date:  2016-08-15

3.  The gastric microbial community, Helicobacter pylori colonization, and disease.

Authors:  Miriam E Martin; Jay V Solnick
Journal:  Gut Microbes       Date:  2014-03-18

Review 4.  Role of Helicobacter pylori infection in gastric carcinogenesis: Current knowledge and future directions.

Authors:  Aleksandra Sokic-Milutinovic; Tamara Alempijevic; Tomica Milosavljevic
Journal:  World J Gastroenterol       Date:  2015-11-07       Impact factor: 5.742

5.  Age-dependent association among Helicobacter pylori infection, serum pepsinogen levels and immune response of children to live oral cholera vaccine CVD 103-HgR.

Authors:  Khitam Muhsen; Rosanna Lagos; Mardi K Reymann; David Y Graham; Marcela F Pasetti; Myron M Levine
Journal:  PLoS One       Date:  2014-01-15       Impact factor: 3.240

Review 6.  Complex adaptive immunity to enteric fevers in humans: lessons learned and the path forward.

Authors:  Marcelo B Sztein; Rosangela Salerno-Goncalves; Monica A McArthur
Journal:  Front Immunol       Date:  2014-10-27       Impact factor: 7.561

7.  Pre-existing Helicobacter pylori serum IgG enhances the vibriocidal antibody response to CVD 103-HgR live oral cholera vaccine in Malian adults.

Authors:  Khitam Muhsen; Samba O Sow; Milagritos D Tapia; Fadima C Haidara; Mardi Reymann; Valeria Asato; Wilbur H Chen; Marcela F Pasetti; Myron M Levine
Journal:  Sci Rep       Date:  2020-10-09       Impact factor: 4.379

8.  Relationship Between Helicobacter pylori IgG Seroprevalence and the Immune Response to Poliovirus Vaccine Among School-Age Children From a Population With Near-Universal Immunity Level.

Authors:  Layaly Badran Abu Zher; Merav Weil; Eias Kassem; Nael Elias; Myron M Levine; Khitam Muhsen
Journal:  Front Med (Lausanne)       Date:  2022-01-20

9.  Reduced Ebola vaccine responses in CMV+ young adults is associated with expansion of CD57+KLRG1+ T cells.

Authors:  Georgina Bowyer; Hannah Sharpe; Navin Venkatraman; Pierre Birahim Ndiaye; Djibril Wade; Nicole Brenner; Alex Mentzer; Catherine Mair; Tim Waterboer; Teresa Lambe; Tandakha Dieye; Souleymane Mboup; Adrian V S Hill; Katie J Ewer
Journal:  J Exp Med       Date:  2020-07-06       Impact factor: 14.307

Review 10.  Nano and Microparticles as Potential Oral Vaccine Carriers and Adjuvants Against Infectious Diseases.

Authors:  Seyed Davoud Jazayeri; Hui Xuan Lim; Kamyar Shameli; Swee Keong Yeap; Chit Laa Poh
Journal:  Front Pharmacol       Date:  2021-06-02       Impact factor: 5.810

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.